Bristol-Myers Squibb Company (BMY) EBITDA Margin: 30.18%
Is Bristol-Myers Squibb Company’s EBITDA margin high or low?
Bristol-Myers Squibb Company's EBITDA margin of 30.18% is in line with its 5-year average of 29.39%, around the middle of its 5-year range (6.56%–43.37%).
As of Thursday, June 18, 2026. 64.29% above its 12-month average of 18.37%.
BMY EBITDA Margin Chart
BMY Average EBITDA Margin Chart
BMY Current vs Average EBITDA Margin Chart
BMY EBITDA Margin Metrics
EBITDA MARGIN
30.18%
EBITDA MARGIN AVG TTM
18.37%
EBITDA MARGIN AVG 3Y
30.35%
EBITDA MARGIN AVG 5Y
29.39%
EBITDA MARGIN AVG 10Y
28.48%
EBITDA MARGIN AVG 15Y
27.86%
EBITDA MARGIN AVG 20Y
27.36%
CURRENT VS TTM AVG
+64.29%
CURRENT VS 3Y AVG
-0.57%
CURRENT VS 5Y AVG
+2.67%
CURRENT VS 10Y AVG
+5.96%
CURRENT VS 15Y AVG
+8.33%
CURRENT VS 20Y AVG
+10.31%
BMY Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $112.89B | 30.18% | 18.37% | 30.35% | 29.39% |
| Stryker Corporation (SYK)vs › | $115.45B | 25.14% | 23.50% | 23.36% | 22.67% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $116.49B | 40.28% | 22.34% | 35.25% | 38.74% |
| Medtronic plc (MDT)vs › | $103.29B | 26.97% | 27.23% | 26.91% | 26.72% |
| CVS Health Corporation (CVS)vs › | $127.73B | 2.45% | 3.06% | 3.76% | 4.57% |
| Danaher Corporation (DHR)vs › | $128.06B | 28.27% | 29.38% | 31.44% | 31.51% |
| HCA Healthcare, Inc. (HCA)vs › | $86.23B | 20.64% | 20.16% | 20.49% | 20.85% |
| Elevance Health Inc. (ELV)vs › | $84.97B | 4.85% | 5.39% | 5.84% | 6.22% |
| Intuitive Surgical, Inc. (ISRG)vs › | $142.44B | 39.63% | 38.59% | 35.51% | 35.18% |
| Pfizer Inc. (PFE)vs › | $147.73B | 24.12% | 26.30% | 27.39% | 29.84% |
Margin Comparison
Gross Margin
68.8%
EBITDA Margin
30.2%
Operating Margin
25.7%
Net Margin
15.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Bristol-Myers Squibb Company EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company EBITDA Margin FAQ
- What is the EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The EBITDA margin for BMY stock is 30.18%.
- Is Bristol-Myers Squibb Company's EBITDA margin high or low?
- Bristol-Myers Squibb Company's EBITDA margin of 30.18% is in line with its 5-year average of 29.39%, around the middle of its 5-year range (6.56%–43.37%).
- What is the TTM average EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The TTM average EBITDA margin for BMY stock is 18.37%.
- What is the 3Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The 3Y average EBITDA margin for BMY stock is 30.35%.
- What is the 5Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The 5Y average EBITDA margin for BMY stock is 29.39%.
- What is the 10Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The 10Y average EBITDA margin for BMY stock is 28.48%.
- What is the 15Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The 15Y average EBITDA margin for BMY stock is 27.86%.
- What is the 20Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?
- The 20Y average EBITDA margin for BMY stock is 27.36%.
Bristol-Myers Squibb Company EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 30.18% |
| 2024-12-31 | 6.56% |
| 2023-12-31 | 43.03% |
| 2022-12-31 | 41.64% |
| 2021-12-31 | 43.37% |
| 2020-12-31 | 11.59% |
| 2019-12-31 | 28.22% |
| 2018-12-31 | 30.09% |
| 2017-12-31 | 29.44% |
| 2016-12-31 | 33.27% |
| 2015-12-31 | 15.92% |
| 2014-12-31 | 19.21% |
| 2013-12-31 | 23.52% |
| 2012-12-31 | 18.18% |
| 2011-12-31 | 36.50% |
| 2010-12-31 | 35.02% |
| 2009-12-31 | 34.52% |
| 2008-12-31 | 28.65% |
| 2007-12-31 | 22.84% |
| 2006-12-31 | 18.49% |
| 2005-12-31 | 24.29% |
| 2004-12-31 | 27.72% |
| 2003-12-31 | 27.39% |
| 2002-12-31 | 26.69% |
| 2001-12-31 | 30.30% |
| 2000-12-31 | 36.96% |
| 1999-12-31 | 29.26% |
| 1998-12-31 | 27.79% |
| 1997-12-31 | 30.11% |
| 1996-12-31 | 29.68% |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner